Celsion Corporation (CLSN) Stock: Gaining On Publication Of Clinical Data

Celsion Corporation (NASDAQ: CLSN) is having an incredibly strong start to the trading session today, and for good reason. The company published positive clinical data, leading to excitement among investors and sending the stock screaming for the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:09), CLSN is trading at $4.70 per share after a gain of $0.55 per share (13.25%) thus far today.

CLSN Gains On The Publication Of Clinical Data

As mentioned above, Celsion Corporation is having an overwhelmingly strong day in the market today after the company announced the publication of a manuscript titled “Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.” The data was published in Clinical Cancer Research, which is a high impact, peer-reviewed medical journal.

The article that was published reports on one of the largest controlled studies in hepatocellular carcinoma, also known as HCC. The data provides a comprehensive review of ThermoDox®, the proprietary heat-activated liposomal encapsulation of doxorubicin created by CLSN for the treatment of primary liver cancer.

The study the article was centered around included 701 patients. The article explores the hypotheses that ThermoDox, when used in combination with Radiofrequency Ablation standardized to a minimum dwell time of 45 minutes, may increase the survival of patients with HCC.

Currently, CLSN is working to confirm this hypothesis with a Phase III OPTIMA Study. The study is a global, pivotal, double-blind, placebo-controlled clinical trial. The trial has been developed in consultation with leading primary liver cancer researchers and statistical and regulatory experts. In a statement, Professor Won Young Tak, M.D., Ph.D., lead investigator in South Korea for the CLSN HEAT and OPTIMA studies, had the following to offer:

There is clear evidence that the duration of the RFA regimen is critical when treating patients with ThermoDox®, and the totality of the data presented in the newly published article in the peer-reviewed journal, Clinical Cancer Research, demonstrates that ThermoDox® plus standardized RFA has a strong potential to serve as a curative therapy for patients with liver cancer… The OPTIMA Study is designed to validate this approach in an indication where there exists a strong unmet need for effective treatment options.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on CLSN. In particular, we’re interested in following the ongoing OPTIMA study and excited to learn the results of the study, considering the overwhelmingly positive data the company has recently released with regard to the treatment. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

Leave a Comment